CANCER:

Endometrial Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

›

MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) dostarlimab Sensitive : C3 IGCS 2022 - 2wk	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks dostarlimab Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
MSH2 deletion + MSH6 deletion	Endometrial Cancer	MSH2 deletion + MSH6 deletion	Endometrial Cancer	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) dostarlimab Sensitive : C3 IGCS 2022 - 2wk	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks dostarlimab Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
MLH1 deletion+ PMS2 deletion	Endometrial Cancer	MLH1 deletion+ PMS2 deletion	Endometrial Cancer	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) dostarlimab Sensitive : C3 IGCS 2022 - 2wk	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks dostarlimab Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : A1 ESMO 2022 - 3wk	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks dostarlimab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A1 ESMO 2022 - 3wk	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks pembrolizumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
ALPP expression	Endometrial Cancer	ALPP expression	Endometrial Cancer	anti-ALPP CAR-T cells Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) anti-ALPP CAR-T cells Sensitive : C3 ESMO 2022 - 3wk	anti-ALPP CAR-T cells Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks anti-ALPP CAR-T cells Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
HER-2 expression	Endometrial Adenocarcinoma	HER-2 expression	Endometrial Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
NTRK1 fusion	Endometrial Cancer	NTRK1 fusion	Endometrial Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Endometrial Cancer	NTRK2 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Endometrial Cancer	NTRK3 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + paclitaxel + SGN-15 Sensitive: A2 - Guideline cisplatin + paclitaxel + SGN-15 Sensitive : A2	cisplatin + paclitaxel + SGN-15 Sensitive: A2 - Guideline cisplatin + paclitaxel + SGN-15 Sensitive : A2
NTRK1 fusion	Endometrial Cancer	NTRK1 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
HER-2 positive	Endometrial Cancer	HER-2 positive	Endometrial Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
TMB-H	Endometrial Cancer	TMB-H	Endometrial Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	paclitaxel + ifosfamide Sensitive: A2 - Guideline paclitaxel + ifosfamide Sensitive : A2	paclitaxel + ifosfamide Sensitive: A2 - Guideline paclitaxel + ifosfamide Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + SGN-15 Sensitive: A2 - Guideline cisplatin + SGN-15 Sensitive : A2	cisplatin + SGN-15 Sensitive: A2 - Guideline cisplatin + SGN-15 Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	SGN-15 Sensitive: A2 - Guideline SGN-15 Sensitive : A2	SGN-15 Sensitive: A2 - Guideline SGN-15 Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
NTRK3 fusion	Endometrial Cancer	NTRK3 fusion	Endometrial Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Endometrial Cancer	NTRK2 fusion	Endometrial Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline tamoxifen + medroxyprogesterone Sensitive : A2	tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline tamoxifen + medroxyprogesterone Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2	fulvestrant Sensitive: A2 - Guideline fulvestrant Sensitive : A2

Endometrial Cancer

Associations(181)

Associations
(181)